Airdoc 鹰瞳科技
HK-listed AI retinal screening for eye and chronic-disease risk
Overview
Airdoc (鹰瞳科技), HK-listed since 2021 (2251.HK), builds AI fundus-camera systems that flag 35-plus eye conditions and chronic-disease risk markers like diabetes and hypertension from one retinal scan. NMPA Class III and EU MDR certified; sold through hospitals and health-check partners.
What you can produce with Airdoc 鹰瞳科技
- AI fundus-camera hardware (AI-FD16H, mydriasis-free, 12MP)
- Screens 35+ eye conditions plus 9 chronic-disease risk markers from one retinal scan
- NMPA Class III certified — first in its category, August 2020
- EU MDR Class IIb CE certification
- Airdoc Medical / Airdoc Health / Airdoc Eye Health product lines
- Deployed across hospitals, insurers and health-check centers; ~30 million scans served
ASEAN Perspective
Airdoc 鹰瞳科技 in Southeast Asia
ASEAN-region availability and pricing notes coming soon. Drop the editorial team a note via /contact/ if you can supply local context (Singapore/Malaysia/Indonesia/Thailand/Vietnam).
A single retinal photo, read by Airdoc's model in about three minutes, is enough to flag diabetic retinopathy and eight other chronic-disease risk indicators alongside 35 named eye conditions — a genuinely differentiated approach versus single-purpose screening tools. It was the first ophthalmic AI in China to earn NMPA Class III clearance (August 2020), later added EU MDR Class IIb certification, and a validation study put its diabetic retinopathy detection at 90.8% sensitivity and 98.5% specificity against ophthalmologist reads.
The business side is less settled: H1 2023 revenue grew 120.6% to RMB82.5 million, but the company posted a net loss of roughly RMB23.3 million in its most recent reported quarter, and it sells through hospitals, insurers and health-check chains rather than direct to patients. Nearly 30 million scans served is a real number, but there's no self-serve product, no public API and no ASEAN distribution confirmed — regional buyers need a local device-approval and channel partner.
What people say
Airdoc doesn't show up on consumer review platforms in any meaningful way — it's sold through hospitals, insurers and corporate health-check programmes, not as an app people download and rate. What exists instead is clinical literature and financial disclosure, which paint a more mixed picture than the marketing copy.
On the clinical side the numbers hold up. A multicentre validation study found Airdoc's system detected diabetic retinopathy in 145 of 900 participants (16.3%) versus 143 (16.1%) found by ophthalmologists, with sensitivity of 90.79%, specificity of 98.5%, and an AUC of 0.946 — solid agreement with human graders. The company was first in China to win NMPA Class III clearance for an AI ophthalmic screening product (August 2020), a category where autonomous diagnostic calls need explicit regulatory sign-off, and later added EU MDR Class IIb certification for the European market.
Financially it's a story of fast top-line growth against thin or negative margins. First-half 2023 revenue rose 120.6% year-on-year to RMB82.5 million, split across three business lines — Airdoc Medical (RMB29.8m, up 137.3%), Airdoc Health (RMB21.7m, up 26.0%) and Airdoc Eye Health (RMB31.0m, up 307%). But more recent quarterly filings show revenue around RMB89.6 million against a net loss of roughly RMB23.3 million, so the growth hasn't yet turned into consistent profitability — typical for a young medical-AI company still building out its hospital and insurer channel.
The company claims almost 30 million users served and describes owning the world's largest retinal image database, both figures that come from its own press materials rather than an audited third party. There's no public pricing, no self-serve trial, and deployment happens through its own portable fundus cameras (the AI-FD16H, a 12-megapixel mydriasis-free unit) sold as part of a bundled hardware-plus-software offering. For a health system or insurer evaluating retinal AI, the regulatory record is the strongest signal here — the financials are still a work in progress.
Summary of public user & expert reviews, compiled by RECATOOLS.
About this listing
This entry was compiled from publicly available data including Airdoc 鹰瞳科技's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Airdoc 鹰瞳科技 unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Airdoc 鹰瞳科技 directly →
Spotted something out of date? Suggest an update →
Airdoc 鹰瞳科技 in the news
Cybersecurity
Two Rival Powers, One Police Force: Researchers Say China- and India-Linked Groups Separat...
Cybersecurity
Taiwan Charges Two Executives Over a LINE-Account Leasing Scheme Prosecutors Link to Chine...
AI & ML
China's Biren Raises ~$900M for AI Chips — a Sanctioned Challenger Betting Big Against Nvi...
Alternatives to Airdoc 鹰瞳科技
More in Healthcare
